Evaxion A/S · NASDAQ:EVAX
Evaxion A/S — Evaxion Biotech — Investor Presentation (April 2024)
43 slides from Evaxion A/S's investor presentation, April 2024
Slide 1: AI-Immunology Powered Vaccines
April 2024 evaxion-biotech.com AI-ImmunologyTM Powered Vaccines EVAX:NASDAQ
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “m
Slide 3: Who We Are
Who We Are Evaxion is a pioneering TechBio company with a validated and leading AI–platform, AI-Immunology™, for fast and effective vaccine target discovery, design and development AI-Immunology™ allows for groundbreaking development of novel personalized and precision vaccines for cancer and infect
Slide 4: Why Are We Here: Saving and Improving Lives with AI-Immunology
Why Are We Here: Saving and Improving Lives with AI- Immunology™ 10 million deaths a year due to cancer* 7.8 million deaths a year due to infectious diseases** © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2024. * Source: WHO, ** Source: IHME, 4
Slide 5: Strategy: Three-Pronged Business Model Based upon AI-Immunology
Strategy: Three-Pronged Business Model Based upon AI-Immunology™ Multi-partner approach to value realization TARGETS Multi-partner approach focused around single or multiple vaccine target discovery, design and development agreements PIPELINE Own development programs for select high value programs;
Slide 6: Strong Multidisciplinary Capability Set and State of the Art Facilities
We Have Built a Strong Multidisciplinary Capability Set and State of the Art Facilities Disease Biology Translational Target Discovery Medicine AI-Immunology™ Clinical Vaccine target discovery, Antigen Development design & development Design Vaccine & CMC Adjuvant Design Preclinical Development © Ev
Slide 7: AI-Immunology Platform and Multidisciplinary Capability Set Drive Differentiation
Our AI-Immunology™ Platform and Multidisciplinary Capability Set Drive Differentiation • Our multidisciplinary capability set allows for: VALUE OF PLATFORM • Continuous iterative learning loops • Ongoing expansion of data sets with RISK OF FAILURE proprietary data • Rapid validation of AI prediction
Slide 8: Pipeline: Demonstrating Performance and Scalability of AI-Immunology Platform
Pipeline: Demonstrating the Performance and Scalability of Our AI-Immunology™ Platform * © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2024. *The data generated in the EVX-02 program actively informs the 8 development of the second generation EVX-03 DNA vaccine
Slide 9: Strong Leadership with Extensive Experience Across All Relevant Fields
Strong Leadership with Extensive Experience Across All Relevant Fields Board of Directors • Marianne Søgaard Chair, former tech lawyer and equity partner • Roberto Prego Former Teva (head of Latin America) • Lars Holtug Certified Public Accountant Chief Executive Chief Financial & Chief AI & Culture
Slide 10: Addressing a $277 Billion and Growing Market for Cancer Immunotherapy
We Are Addressing a $277 Billion Increased Deal-Making Across and Growing Market for Cancer the Vaccine Space Immunotherapy Alone Cancer Cancer • Cancer immunotherapy market estimated to grow to $277 billion • Moderna-Merck partnership. Upfront 200M (2016) + option to by 2030* exercise $250M (Oct 20
Slide 11: Recent Highlights Confirm Strong Strategy Execution
Recent Highlights Confirm Strong Strategy Execution Closing of $15 Million Public Collaboration with Private Placement with Offering with Participation Afrigen Biologics Participation of MSD GHI MSD GHI OCT 31, NOV 15, DEC 8, JAN 24, FEB 20, Apr 2, 2023 2023 2023 2024 2024 2024 SEP 20, DEC 21, FEB 5
Slide 12: Several Important Near-Term Milestones
Several Important Near-Term Milestones Milestones Target EVX-B1 Conclusion of final MTA study with potential partner Q1 2024 AI-Immunology™ Launch of EDEN™ model version 5.0 Mid 2024 EVX-B2-mRNA EVX-B2-mRNA preclinical Proof-of-Concept obtained Q3 2024 EVX-01 Phase 2 one-year readout Q3 2024 Conclus
Slide 13: Evaxion Is a Pioneering TechBio Company Based on AI-Immunology Platform
Evaxion Is a Pioneering TechBio Company Based on the Leading AI-Immunology™ Platform Founded in 2008 as an AI-Immunology™ company. Has extensively collected and applied data as well as refined and validated our AI platform for 15 years Three-pronged business model: Targets, Pipeline and Responders.
Slide 14: The AI-Immunology Platform
The AI-Immunology™ Click to add title Platform © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2024. 14
Slide 15: The Key Areas of AI-Immunology
The Key Areas of AI-Immunology™ DISEASE DECODING IMMUNE RESPONSE DECODING VACCINE DESIGN © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2024. 15
Slide 16: AI-Immunology is an Ensemble of Smaller Building Blocks
AI-Immunology™ is an Ensemble of Smaller Building Blocks Utilized Across the AI-Immunology™ Models SNVs EvaxMHC Precision design DISEASE DECODING Frameshifts HLA typing BIFROST HLA loss Epitope hotspots Personalized design © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 20
Slide 17: The Building Blocks of AI-Immunology
The Building Blocks of AI-Immunology™ 1 DISEASE DECODING SNVs Frameshifts Gene fusions HLA loss ERV antigens TME impact Clonality Expression Bacterial antigens Viral antigens Antigen conservation Treatment effect Neoantigens 2 IMMUNE RESPONSE DECODING EvaxMHC HLA typing HLA frequencies Distance to s
Slide 18: The Models of AI-Immunology
The Models of AI-Immunology™ PIONEER™ ObsERV™ SNVs Frameshifts Gene fusions HLA loss HLA loss ERV antigens Expression Expression Clonality Neoantigens EvaxMHC HLA typing EvaxMHC HLA typing Distance to self Antigen quality Antigen safety Personalized design Antigen quality Antigen safety Personalized
Slide 19: AI-Immunology: A Unique Differentiator with Interrelated AI Prediction Models
AI-Immunology™ - A Unique Differentiator with Interrelated AI Prediction Models and Leading Multidisciplinary Capabilities PIONEER™ patient-specific neoantigens R™ NEE EDEN™ O ED PI B-cell antigens EN ™ ™ EER ON PI gy Infe ObsERV™ o-oncolo ObsERV™ ctious Diseas patient-specific ERV antigens AI-Immun
Slide 20: AI-Immunology Platform is Delivery Modality Agnostic
A Unique Differentiation: The AI-Immunology™ Platform is Delivery Modality Agnostic Competitor landscape personalized neoantigen vaccines • We have demonstrated that a key to more effective vaccines is the Company Format Phase performance power of our AI platform Moderna/Merck mRNA 3 and the quality
Slide 21: Building Block Architecture Enables Scaling to Other Therapeutic Areas
Building Block Architecture Enables Scaling to Other Therapeutic Areas CA NC ER © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2024. 21
Slide 22: The AI-Immunology Powered Vaccine Pipeline
The AI-Immunology™ Click to add title Powered Vaccine Pipeline © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2024. 22
Slide 23: Pipeline: Demonstrating Performance and Scalability of AI-Immunology Platform
Pipeline: Demonstrating the Performance and Scalability of Our AI-Immunology™ Platform * © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2024. *The data generated in the EVX-02 program actively informs the 23 development of the second generation EVX-03 DNA vaccine
Slide 24: EVX-01 with Standard Therapy Shows Overall Response Rate of 67%
EVX-01 in Combination with Standard Therapy Shows Overall Response Rate of 67% in Clinical Phase 1/2 in Patients with Metastatic Melanoma Study highlights • 12 patients in total, with 8 showing an objective response to treatment (ORR 67%) • 2 complete responders • Treatment: 6 biweekly EVX-01 inject
Slide 25: EVX-01 PIONEER Identified Vaccine Targets Highly Correlate with Survival
EVX-01 - PIONEER™ Identified Vaccine Targets Highly Correlate with Survival High prediction score of neoantigens (n=6) (N=6) Low prediction score of neoantigens (n=6) • AI response prediction (PIONEER™ score) builds on the presence of high- Progression Free Survival Fraction of patients with quality
Slide 26: EVX-01 Induces a Dose-Dependent Immune Response
EVX-01 Induces a Dose- Dependent Immune Response against the Patients’ Cancer Neoantigen-specific T cells (SFU) • A higher dose induced higher neoantigen immune responses which may result in stronger tumor killing activity of EVX-01 • Specific immune responses against neoantigens identified by PIONE
Slide 27: EVX-01 Clinical Phase 1/2 Summary
EVX-01 – Clinical Phase 1/2 Summary With AI-Immunology™ identified targets we have demonstrated longer progression-free survival of patients Phase 1/2 Phase 2 High overall response rate with clinical Phase 2 initiated in metastatic response in all high dose group patients melanoma with high dose EVX
Slide 28: EVX-01 Phase 2 Trial Enrolling Patients in Australia/Europe
EVX-01 Phase 2 Trial Enrolling Patients in Australia/Europe Enrolled 16 patients with metastatic melanoma Conducted in collaboration with Merck & Co., Inc (MSD) EVX-01 Priming EVX-01 Boosting Production (To activate T-cells) (To maintain level of activated T-cells) Timeline for each W1 W12 W14 W16 W
Slide 29: Encouraging Initial EVX-01 Phase 2 Trial Results
Engouraging Initial EVX-01 Phase 2 Trial Results Response to vaccine neoantigens IFNγ ELISpot, background subtracted 2000 • Initial data from five patients*: SFUs per 1 x 106 PBMCs • Confirm the favorable safety profile of EVX-01 1500 • Neoantigen specific T-cell reactivity induced 1000 by EVX-01 de
Slide 30: EVX-02 First DNA-Based Personalized Cancer Vaccine Shows Positive Readout
EVX-02 - Evaxion’s First DNA-Based Positive Clinical Personalized Cancer Vaccine Shows Readout* Positive Clinical Readout Study Overview • All 10 EVX-02 completers were relapse-free at last assessment • Phase 1/2 clinical trial of EVX-02 + nivolumab (Opdivo™/standard of care) as adjuvant therapy aft
Slide 31: EVX-03 Believed To Be First Ever Personalized ERV Vaccine
EVX-03 – Believed To Be First Ever Personalized ERV Vaccine DNA-based personalized vaccine armed with molecular immune adjuvant, neoantigens and ERVs • Molecular immune adjuvant attracts antigen presenting cells and augments antigen presentation • The unique technology is fully owned, patent protect
Slide 32: EVX-03 Addition of ERVs Resulted in Very Promising Preclinical Data
EVX-03 - Addition of ERVs Resulted in Very Promising Preclinical Data ERV-Based DNA Vaccine Prevents High ERV Burden is Associated with Tumor Growth in a Preclinical Better Survival in Patients with Few Cancer Model Tumor Mutations (Low TMB) • ERVs are ancient viruses that have 700 integrated into t
Slide 33: EVX-B1 S. aureus Vaccine Candidate Demonstrates High Immunogenicity
EVX-B1 - S. aureus Vaccine Candidate Demonstrates High Immunogenicity and Significant Protection • Multi-component S. aureus vaccine Mouse sepsis model candidate for prevention of Skin and Soft Tissue Infections (SSTI) 100 EVX-B1 • Induction of high IgG titers and Adjuvant 80 potent T-cell response
Slide 34: Encouraging Results for EVX-B1 Vaccine Antigens Against S. aureus
EVX-B1: Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus aureus Infection • Evaxion and its undisclosed collaborator tested Evaxion designed vaccine antigens against Staphylococcus aureus (S. aureus) in a clinically relevant animal model of surgical site infections • The vaccin
Slide 35: EVX-B2 N. gonorrhoeae Vaccine Candidate Induces Significant Protection
EVX-B2 - N. gonorrhoeae Vaccine Candidate Induce Significant Protection and Shows Broad Neutralization Capacity Vaginal colonization model • Multi-component N. gonorrhoeae vaccine candidate containing two 106 Adjuvant top-ranked EDEN™ candidates EVX-B2 Bacterial burden (CFU) 105 • Significant protec
Slide 36: Intellectual Property
Intellectual Click to addProperty title © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2024. 36
Slide 37: Intellectual Property Portfolio Covers AI and Vaccine Candidates
Evaxion’s Intellectual Property Portfolio Broadly Covers AI and Vaccine Candidates for Cancer and Infectious Diseases Evaxion Biotech A/S holds an extensive intellectual property (IP) portfolio The IP portfolio covers strategic parts of the AI-Immunology™ platform and compositions of matter, methods
Slide 38: Corporate Summary
Corporate Summary Click to add title © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2024. 38
Slide 39: Pipeline: Demonstrating Performance and Scalability of AI-Immunology Platform
Pipeline: Demonstrating the Performance and Scalability of Our AI-Immunology™ Platform * © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2024. *The data generated in the EVX-02 program actively informs the 39 development of the second generation EVX-03 DNA vaccine
Slide 40: Capital Structure
Capital Structure Listed on Nasdaq NY under ticker “EVAX” Date of listing: Feb 5, 2021 Headquarters Denmark Employees 40 Average Volume (3M) 687,009 Shares outstanding 52 M MSD GHI ownership Around 15% Capital raised (USD) 107 M Debt (USD) 8 M (long term) © Evaxion Biotech A/S. All rights reserved w
Slide 41: Recent Deals & Partnerships - Overview
Recent Deals & Partnerships - Overview MSD GHI - Discovery Partnership Afrigen - mRNA Gonorrhea Welcome MSD GHI as New Partner Vaccine Description Description • Discovery partnership with MSD around Description • In the recent private placement, MSD undisclosed bacterial pathogen for • Discovery par
Slide 42: Strategy Summary
Strategy Summary The AI-Immunology™ Platform Targets Multiple partnerships in place, several partner • Design and development of personalized discussion ongoing. Dealmaking capacity and precision vaccine candidates being enhanced • AI prediction models trained in cancer and infectious diseases Pipel
Slide 43: Thank You
LinkedIn: CEO Christian Kanstrup evaxion-biotech.com Evaxion Biotech A/S cka@evaxion-biotech.com Thank You AI-ImmunologyTM Powered Vaccines